Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.RXII · Entity 7889 | Chief Business Officer | September 05, 2017 | September 07, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date September 05, 2017 · Filed September 07, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.0001SEC Table I · non-derivative | Direct | 950,312 |
Ending reported balance
After 2017-09-07 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-09-05 · Sale · Disposed 26,181 · Balance 1,100,931 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $0.55 and the highest price at which shares were sold was $0.58.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2017-09-06 · Sale · Disposed 91,907 · Balance 1,009,024 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3: Represents the weighted average sale price. The lowest price at which shares were sold was $0.525 and the highest price at which shares were sold was $0.561.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2017-09-07 · Sale · Disposed 58,712 · Balance 950,312 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4: Represents the weighted average sale price. The lowest price at which shares were sold was $0.52 and the highest price at which shares were sold was $0.545.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $0.55 and the highest price at which shares were sold was $0.58.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected.
F3: Represents the weighted average sale price. The lowest price at which shares were sold was $0.525 and the highest price at which shares were sold was $0.561.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected.
F4: Represents the weighted average sale price. The lowest price at which shares were sold was $0.52 and the highest price at which shares were sold was $0.545.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2017 Filed Sep 7, 2017 20:17 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | SaleCommon stock, par value $0.0001 | 58,712 | $0.53 | $31,017.55 |
DisclosureSEC source: 0001209191-17-051978 · doc4.xml · nonDerivative · entry 3 Eliseev Alexey · CIK 0001694380 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,312 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $0.52 and the highest price at which shares were sold was $0.545.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 06, 2017 Filed Sep 7, 2017 20:17 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | SaleCommon stock, par value $0.0001 | 91,907 | $0.54 | $49,308.11 |
DisclosureSEC source: 0001209191-17-051978 · doc4.xml · nonDerivative · entry 2 Eliseev Alexey · CIK 0001694380 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,024 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $0.525 and the highest price at which shares were sold was $0.561.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:17 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | SaleCommon stock, par value $0.0001 | 26,181 | $0.56 | $14,585.44 |
DisclosureSEC source: 0001209191-17-051978 · doc4.xml · nonDerivative · entry 1 Eliseev Alexey · CIK 0001694380 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100,931 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $0.55 and the highest price at which shares were sold was $0.58.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 20:33 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | SaleCommon stock, $0.0001 par value | 23,200 | $0.57 | $13,182.24 |
DisclosureSEC source: 0001209191-17-051112 · doc4.xml · nonDerivative · entry 1 Eliseev Alexey · CIK 0001694380 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127,112 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The highest price at which shares were sold was $0.58 and the lowest price at which shares were sold was $0.56.The reporting person hereby undertakes to provide upon request to the SEC staff or other appropriate persons full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2017 Filed Jun 9, 2017 21:55 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | ConversionSeries C Convertible Preferred Stock, $0.0001 par value · Derivative | 332,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039027 · doc4.xml · derivative · entry 2 Eliseev Alexey · CIK 0001694380 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 332,499 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C Convertible Preferred Stock automatically converted into common stock upon approval by the Company's stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635 without payment of consideration. The Series C Convertible Preferred Stock have no expiration. F1 · derivative.exercise_date: The Series C Convertible Preferred Stock automatically converted into common stock upon approval by the Company's stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635 without payment of consideration. The Series C Convertible Preferred Stock have no expiration. F1 · derivative.expiration_date: The Series C Convertible Preferred Stock automatically converted into common stock upon approval by the Company's stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635 without payment of consideration. The Series C Convertible Preferred Stock have no expiration. Read SEC document |
| June 09, 2017 Filed Jun 9, 2017 21:55 UTC | Phio Pharmaceuticals Corp. RXII · Entity 7889 | ConversionCommon stock, $0.0001 par value | 332,499 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039027 · doc4.xml · nonDerivative · entry 1 Eliseev Alexey · CIK 0001694380 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C Convertible Preferred Stock automatically converted into common stock upon approval by the Company's stockholders in accordance with the stockholder approval requirements of Nasdaq Marketplace Rule 5635 without payment of consideration. The Series C Convertible Preferred Stock have no expiration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.